1. Home
  2. ETNB vs DAO Comparison

ETNB vs DAO Comparison

Compare ETNB & DAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • DAO
  • Stock Information
  • Founded
  • ETNB 2018
  • DAO 2006
  • Country
  • ETNB United States
  • DAO China
  • Employees
  • ETNB N/A
  • DAO N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • DAO Other Consumer Services
  • Sector
  • ETNB Health Care
  • DAO Real Estate
  • Exchange
  • ETNB Nasdaq
  • DAO Nasdaq
  • Market Cap
  • ETNB 864.2M
  • DAO 884.4M
  • IPO Year
  • ETNB 2019
  • DAO 2019
  • Fundamental
  • Price
  • ETNB $6.31
  • DAO $7.07
  • Analyst Decision
  • ETNB Buy
  • DAO
  • Analyst Count
  • ETNB 7
  • DAO 0
  • Target Price
  • ETNB $30.33
  • DAO N/A
  • AVG Volume (30 Days)
  • ETNB 1.3M
  • DAO 102.5K
  • Earning Date
  • ETNB 02-27-2025
  • DAO 02-27-2025
  • Dividend Yield
  • ETNB N/A
  • DAO N/A
  • EPS Growth
  • ETNB N/A
  • DAO N/A
  • EPS
  • ETNB N/A
  • DAO 0.07
  • Revenue
  • ETNB N/A
  • DAO $822,103,071.00
  • Revenue This Year
  • ETNB N/A
  • DAO $10.00
  • Revenue Next Year
  • ETNB N/A
  • DAO $12.79
  • P/E Ratio
  • ETNB N/A
  • DAO $106.71
  • Revenue Growth
  • ETNB N/A
  • DAO 7.53
  • 52 Week Low
  • ETNB $5.99
  • DAO $2.86
  • 52 Week High
  • ETNB $16.63
  • DAO $8.01
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 31.27
  • DAO 56.61
  • Support Level
  • ETNB $5.99
  • DAO $6.41
  • Resistance Level
  • ETNB $6.65
  • DAO $6.76
  • Average True Range (ATR)
  • ETNB 0.40
  • DAO 0.32
  • MACD
  • ETNB -0.14
  • DAO -0.08
  • Stochastic Oscillator
  • ETNB 15.70
  • DAO 66.67

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About DAO Youdao Inc. each representing one

Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and Youdao Pocket Translator.

Share on Social Networks: